Study identifier:CV181-085
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 4-Week, Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy of Saxagliptin in Combination with Metformin XR 1500 mg versus up-titrated Metformin XR to 2000 mg in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and Exercise and a Stable Dose of Metformin XR 1500 mg
Type 2 Diabetes
Phase 3
No
Saxagliptin, Metformin XR, Placebo matching Metformin XR, Placebo matching Saxagliptin
All
219
Interventional
18 Years - 78 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 May 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Astra Zeneca
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Saxagliptin + Metformin XR + matching Metformin XR placebo (Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo) | Drug: Saxagliptin Tablets, Oral, 5 mg, once daily, 4 weeks Other Name: BMS-477118 Other Name: Onglyza Drug: Metformin XR Tablets, Oral, 1500 mg, once daily, 4 weeks Other Name: Glucophage XR® Drug: Placebo matching Metformin XR Tablets, Oral, 0 mg, once daily, 4 weeks |
Active Comparator: Metformin XR + Metformin XR + matching Saxagliptin placebo (Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo) | Drug: Metformin XR Tablets, Oral, 1500 mg, once daily, 4 weeks Other Name: Glucophage XR® Drug: Metformin XR Tablets, Oral, 500 mg, once daily, 4 weeks Other Name: Glucophage XR® Drug: Placebo matching Saxagliptin Tablets, Oral, 0 mg, once daily, 4 weeks |